Prescribing information

 

   

LUCENTIS offers patients efficacy across multiple indications1

 

The anti-VEGF with the broadest range of retinal indications1

Click the button below to see the key efficacy data for LUCENTIS in the treatment of neovascular (wet) age-related macular degeneration (AMD). 

 

 


Resources to help you with your LUCENTIS patients

 

Preview of an Educational booklet, image of an eye- resources for HCPs.

Resources for HCPs

Access the resources for HCPs >

Document with image of a lady smiling, with text 'understanding diabetic macular oedema (DMO) & what to expect from your lucentis treatment' on it. Resources for HCPs to share with patients.

Resources for HCPs to share with patients

Access the patient resources >

 


We cover a variety of topics about a-VEGF patients, treatment and service impact due to COVID-19 in a variety of webinars and podcasts. 

 

Image icon of a screen with people icons and a speech bubble representing webinar highlights.

Webinar highlights 

Access the webinar highlights >

Image icon of a microphone with sound waves coming out representing opthalmology podcasts.

Ophthalmology podcasts

Access the ophthalmology podcasts >

 


 

*LUCENTIS 0.2 mg is indicated in preterm infants for:1
The treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.

DMO, diabetic macular oedema; CNV, choroidal neovascularisation; HCP, healthcare professional; PDR, proliferative diabetic retinopathy; ROP, retinopathy of prematurity; RVO, retinal vein occlusion; RWE, real-world evidence; T&E, treat & extend; VEGF, vascular endothelial growth factor; wAMD, wet age-related macular degeneration;

 

Reference

  1. Lucentis (ranibizumab) Summary of Product Characteristics, July 2020.
  2. Novartis Data on File. Novartis Pharma AG, LUCDOF21-002, October 2019.
  3. Novartis Data on File. Novartis Pharma AG, LUCDOF21-003, October 2019.
  4. Dorairaj E, et al. Ranibizumab in diabetic macular oedema: 2 year audit data. Presented at ESCRS 2017, Maastricht, The Netherlands.     
  5. Prakash, P, et al. To determine the efficacy of treatment of Ranibizumab over a period of 5 years in patients with DMO at PAH, Harlow, presented at Royal College of Ophthalmology congress 2021.    
  6. Mitchell P, et al. Effectiveness and safety of ranibizumab 0.5 mg in treatment-naïve patients with diabetic macular edema: Results from the real-world global LUMINOUS study. PLoS One. 2020;15(6):32492069.
Rate this content: 
Average: 2.6 (69 votes)
UK | December 2021 | 176510
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]